South China Morning Post has reopened an ingestible-beauty comparison question: whether bovine colostrum — the pre-milk fluid secreted in the first 24–72 hours after calving — is the functional successor to hydrolysed collagen, or just another wellness trend. The framing matters because collagen's category position was earned over a decade of randomised dermatology trials at 5–10 g/day, and any ingredient asked to replace it must clear the same evidentiary bar.

What colostrum actually delivers

Bovine colostrum's cosmetic and supplement pitch rests on an active profile structurally different from collagen:

• Immunoglobulin G (IgG) present at multi-gram-per-litre levels in first-milking colostrum
• Lactoferrin concentrations in the 1–5 g/L range
• Growth factors including IGF-1, TGF-β and EGF at trace but biologically relevant quantities

Formulators re-pitching the ingredient from sports recovery into skin, hair and nail lines cite this composition as the proximate cause for category-crossing use.

Why the collagen bar is hard to clear

Collagen's category advantage rests on two demonstrable claims: hydrolysed peptides (typically 2–10 kDa fragments) reach systemic circulation after oral dosing, and 8–12 weeks of supplementation produces reproducible effects on skin hydration, elasticity and wrinkle depth in randomised trials. Whether colostrum clears both bars at cosmetic doses is the empirical question the SCMP inquiry underlines. The mechanistic case is plausible — growth factors and bioactive peptides could affect dermal matrix turnover — but plausibility is not the same as repeated dermatology RCT data.

Formulation pull

For formulators, colostrum offers categorisation flexibility collagen cannot match. Immunoglobulins and lactoferrin support barrier- and microbiome-adjacent positioning; the ingredient sits naturally in gut-skin axis narratives; and galenic options — powders, capsules, ready-to-drink sachets — slot into existing beauty-from-within SKU templates. INCI disclosure for topical formulations typically lists "Colostrum" when the unprocessed fraction is declared, with processed derivatives named by their processing chemistry.

Compliance friction

Compliance work runs heavier than the formulation case suggests. For oral supplement use in the EU, bovine colostrum sits under the Novel Food regulation with provenance, processing and dosage limits per authorisation; finished-product dossiers require traceability from farm to spray dryer. In the US, GRAS self-affirmed status applies with narrower use conditions than commodity dairy proteins have historically carried. Topical cosmetic use clears a separate bar — INCI nomenclature, allergens disclosure and, in finished-product claims, the cosmetics-versus-drugs line the FDA enforces for structure-function language.

What would move the needle

Three near-term data points would settle the trend question:

• Randomised dermatology trials at 2–5 g/day colostrum doses using corneometry, cutometry and validated wrinkle scoring
• INCI listings for finished cosmetic formulations where colostrum is the declared active rather than a secondary ingredient
• Repeat-purchase and unit-economic disclosure from any major beauty-from-within brand that has shipped colostrum-anchored SKUs at scale

Until at least one of those lands publicly, colostrum is best read as a mechanistically credible, category-crossing candidate — not a structural replacement for collagen's clinical dossier.